Tuesday, May 3, 2011

Xoma botulism treatment starts early-stage government trial

A Xoma Ltd. antibody treatment aimed at preventing and treating botulism poisoning — particularly that caused by a biological weapon — is the focus of an early-stage trial sponsored by the National Institute of Allergy and Infectious Diseases.
The 24-patient Phase I trial at Johns Hopkins University in Baltimore will test the safety of XOMA 3AB, the Berkeley-based company’s (NASDAQ: XOMA) most advanced R&D program. It uses three antibodies that when combined neutralize the botulism neurotoxin at very low doses.

No comments:

Post a Comment